Fisher Funds Management LTD Lowers Stock Holdings in AbbVie Inc. $ABBV

Key Points

• Fisher Funds Management LTD reduced its AbbVie stake by 18.5% in the first quarter, selling 23,961 shares and leaving it with 105,518 shares valued at about $22.95 million.
• AbbVie reported strong quarterly results, with EPS of $2.65 beating estimates and revenue of $15 billion topping expectations, while sales rose 12.4% year over year.
• The company also announced a quarterly dividend of $1.73 per share, and analysts remain generally positive with an average Moderate Buy rating and a $253.43 price target.

Fisher Funds Management LTD cut its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 18.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 105,518 shares of the company's stock after selling 23,961 shares during the quarter. Fisher Funds Management LTD's holdings in AbbVie were worth $22,949,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ABBV. Bank of Jackson Hole Trust boosted its holdings in shares of AbbVie by 0.6% in the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company's stock valued at $1,648,000 after acquiring an additional 44 shares in the last quarter. Eclectic Associates Inc. ADV lifted its position in AbbVie by 0.8% in the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company's stock valued at $1,337,000 after purchasing an additional 45 shares during the period. Imprint Wealth LLC boosted its holdings in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. Hardin Capital Partners LLC increased its position in AbbVie by 1.4% during the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company's stock worth $759,000 after purchasing an additional 46 shares during the period. Finally, Dogwood Wealth Management LLC raised its stake in shares of AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company's stock worth $108,000 after buying an additional 46 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

Shares of ABBV opened at $216.63 on Monday. The firm has a 50 day simple moving average of $212.18 and a 200-day simple moving average of $218.72. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81. The stock has a market cap of $382.74 billion, a price-to-earnings ratio of 106.71, a price-to-earnings-growth ratio of 0.66 and a beta of 0.32.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the previous year, the firm posted $2.46 EPS. The company's quarterly revenue was up 12.4% compared to the same quarter last year. On average, equities analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie's payout ratio is 340.89%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ABBV. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $240.00 price objective on shares of AbbVie in a report on Thursday, April 30th. Guggenheim restated a "buy" rating and set a $249.00 target price on shares of AbbVie in a research report on Friday, May 1st. Royal Bank Of Canada began coverage on shares of AbbVie in a research note on Tuesday, February 24th. They set an "outperform" rating and a $260.00 price target on the stock. Bank of America upgraded shares of AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 price objective for the company in a research note on Thursday, April 30th. Finally, Canaccord Genuity Group boosted their price objective on shares of AbbVie from $262.00 to $265.00 and gave the stock a "buy" rating in a report on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $253.43.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.